Replimune Group (REPL) Competitors $9.55 +0.40 (+4.37%) Closing price 07/2/2025 04:00 PM EasternExtended Trading$9.60 +0.05 (+0.52%) As of 07/2/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock REPL vs. CRNX, VKTX, ALVO, CPRX, HCM, IMVT, OGN, MIRM, AMRX, and IBRXShould you be buying Replimune Group stock or one of its competitors? The main competitors of Replimune Group include Crinetics Pharmaceuticals (CRNX), Viking Therapeutics (VKTX), Alvotech (ALVO), Catalyst Pharmaceuticals (CPRX), HUTCHMED (HCM), Immunovant (IMVT), Organon & Co. (OGN), Mirum Pharmaceuticals (MIRM), Amneal Pharmaceuticals (AMRX), and ImmunityBio (IBRX). These companies are all part of the "pharmaceutical products" industry. Replimune Group vs. Its Competitors Crinetics Pharmaceuticals Viking Therapeutics Alvotech Catalyst Pharmaceuticals HUTCHMED Immunovant Organon & Co. Mirum Pharmaceuticals Amneal Pharmaceuticals ImmunityBio Replimune Group (NASDAQ:REPL) and Crinetics Pharmaceuticals (NASDAQ:CRNX) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, analyst recommendations, valuation, dividends and media sentiment. Do analysts rate REPL or CRNX? Replimune Group currently has a consensus target price of $20.83, indicating a potential upside of 118.15%. Crinetics Pharmaceuticals has a consensus target price of $71.75, indicating a potential upside of 143.72%. Given Crinetics Pharmaceuticals' higher possible upside, analysts clearly believe Crinetics Pharmaceuticals is more favorable than Replimune Group.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Replimune Group 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13Crinetics Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.90 Which has more risk & volatility, REPL or CRNX? Replimune Group has a beta of 0.61, indicating that its share price is 39% less volatile than the S&P 500. Comparatively, Crinetics Pharmaceuticals has a beta of 0.25, indicating that its share price is 75% less volatile than the S&P 500. Is REPL or CRNX more profitable? Crinetics Pharmaceuticals' return on equity of -30.95% beat Replimune Group's return on equity.Company Net Margins Return on Equity Return on Assets Replimune GroupN/A -57.98% -45.21% Crinetics Pharmaceuticals N/A -30.95%-28.12% Do insiders and institutionals believe in REPL or CRNX? 92.5% of Replimune Group shares are owned by institutional investors. Comparatively, 98.5% of Crinetics Pharmaceuticals shares are owned by institutional investors. 8.8% of Replimune Group shares are owned by company insiders. Comparatively, 4.6% of Crinetics Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Does the media prefer REPL or CRNX? In the previous week, Crinetics Pharmaceuticals had 3 more articles in the media than Replimune Group. MarketBeat recorded 5 mentions for Crinetics Pharmaceuticals and 2 mentions for Replimune Group. Crinetics Pharmaceuticals' average media sentiment score of 0.50 beat Replimune Group's score of 0.47 indicating that Crinetics Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Replimune Group 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Crinetics Pharmaceuticals 0 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has preferable earnings & valuation, REPL or CRNX? Replimune Group has higher earnings, but lower revenue than Crinetics Pharmaceuticals. Crinetics Pharmaceuticals is trading at a lower price-to-earnings ratio than Replimune Group, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioReplimune GroupN/AN/A-$247.30M-$3.07-3.11Crinetics Pharmaceuticals$1.04M2,650.45-$298.41M-$3.82-7.71 SummaryCrinetics Pharmaceuticals beats Replimune Group on 8 of the 15 factors compared between the two stocks. Get Replimune Group News Delivered to You Automatically Sign up to receive the latest news and ratings for REPL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding REPL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart REPL vs. The Competition Export to ExcelMetricReplimune GroupMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$705.34M$2.88B$5.54B$8.87BDividend YieldN/A2.64%5.39%4.10%P/E Ratio-3.1121.3126.1719.90Price / SalesN/A278.47413.55113.66Price / CashN/A41.4736.1356.90Price / Book1.777.518.025.38Net Income-$247.30M-$55.05M$3.15B$248.50M7 Day Performance0.95%2.07%1.48%2.06%1 Month Performance-0.83%4.84%3.66%4.86%1 Year Performance18.05%5.37%34.68%20.24% Replimune Group Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)REPLReplimune Group4.0027 of 5 stars$9.55+4.4%$20.83+118.2%+14.1%$705.34MN/A-3.11210CRNXCrinetics Pharmaceuticals3.5977 of 5 stars$29.91-0.8%$74.56+149.3%-35.4%$2.80B$760K-7.83210VKTXViking Therapeutics4.1768 of 5 stars$24.86-4.4%$87.15+250.6%-46.2%$2.79BN/A-21.6220ALVOAlvotech3.3704 of 5 stars$9.13-2.4%$18.00+97.2%-27.0%$2.75B$491.98M24.681,032CPRXCatalyst Pharmaceuticals4.9286 of 5 stars$22.12-1.6%$32.83+48.4%+35.8%$2.70B$491.73M14.0980Positive NewsHCMHUTCHMED1.7864 of 5 stars$15.21+2.5%$19.00+24.9%-8.9%$2.65B$630.20M0.001,811Positive NewsIMVTImmunovant2.2293 of 5 stars$15.47-2.1%$38.33+147.8%-36.6%$2.64BN/A-5.65120Positive NewsOGNOrganon & Co.4.8241 of 5 stars$9.82+0.7%$18.00+83.3%-49.5%$2.55B$6.40B3.414,000Trending NewsMIRMMirum Pharmaceuticals3.4615 of 5 stars$50.28-0.1%$65.50+30.3%+45.8%$2.49B$336.89M-31.23140Positive NewsAMRXAmneal Pharmaceuticals3.3512 of 5 stars$7.91+1.2%$11.60+46.6%+28.0%$2.48B$2.79B-197.708,100IBRXImmunityBio2.0689 of 5 stars$2.76-3.8%$12.25+343.8%-57.3%$2.44B$14.74M-4.76590 Related Companies and Tools Related Companies Crinetics Pharmaceuticals Alternatives Viking Therapeutics Alternatives Alvotech Alternatives Catalyst Pharmaceuticals Alternatives HUTCHMED Alternatives Immunovant Alternatives Organon & Co. Alternatives Mirum Pharmaceuticals Alternatives Amneal Pharmaceuticals Alternatives ImmunityBio Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:REPL) was last updated on 7/3/2025 by MarketBeat.com Staff From Our PartnersHere's the last trade you should make before heading out for the weekend tomorrow.Make this one trade at 2:59 PM on Friday afternoon, and you'll thank me on Monday morning.Timothy Sykes | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Crypto Is Set to Explode in JanuaryFree summit: How to profit from the Coinbase-Deribit deal Our hedge fund experts know exactly what this mea...Crypto 101 Media | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Replimune Group, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Replimune Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
